Valuing Health States for Use in Cost-Effectiveness Analysis

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.9, 2008-01, pp. : 769-779

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine Shabaruddin Fatiha H

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

The Use of Meta-Analysis in Cost-Effectiveness Analysis: Issues and Recommendations

By Saint S.

PharmacoEconomics, Vol. 15, Iss. 1, 1999-01 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

Health Utilities in Alzheimers Disease and Implications for Cost-Effectiveness Analysis

By Neumann Peter J.

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 537-541

Adis International

Access to resources Recommend Favorite

Estimating `Costs' for Cost-Effectiveness Analysis

By Miners Alec

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 745-751

Adis International

Access to resources Recommend Favorite

Subgroups and Heterogeneity in Cost-Effectiveness Analysis

By Sculpher Mark

PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. : 799-806

Adis International

Access to resources Recommend Favorite